NCT01978548: A Study to Evaluate the Effects of JNJ-54861911 on Amyloid Beta Processing in Cerebrospinal Fluid and Plasma in Patients With Prodromal Alzheimer's Disease |
|
|
| Completed | 1 | 45 | Europe | JNJ-54861911 10 mg, JNJ-54861911 50 mg, Placebo | Janssen Research & Development, LLC | Alzheimer Disease | 04/15 | 04/15 | | |
NCT02360657: Study Investigating the Effects of JNJ-54861911 on Amyloid-beta Processing in Cerebrospinal Fluid (CSF) and Plasma in Japanese Participants Asymptomatic at Risk for Alzheimer Dementia |
|
|
| Completed | 1 | 18 | Japan | JNJ-54861911, 10 mg, JNJ-54861911, 50 mg, Placebo | Janssen Pharmaceutical K.K. | Alzheimer's Disease | 09/15 | 09/15 | | |
